Spondyloarthritis & psoriatic arthritis
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study
Authors' conclusion
Patients with dactylitis at baseline were associated with higher burden of disease. Secukinumab provided sustained improvements across all clinical outcomes, QoL and inhibition of radiographic progression in PsA patients with dactylitis at baseline over 2 years.
Study context
- Population
- Patients with active psoriatic arthritis (PsA) with dactylitis at baseline (Leeds Dactylitis Index), FUTURE 5 study389 with dactylitis at baseline
- Participants
- 996 patients
- Comparison
- Secukinumab 300 mg loading dose (LD), 150 mg LD or 150 mg without LD vs placebo, in PsA patients with dactylitis at baseline
Methodological detailsexploratory analyses
- Exploratory analyses
Primary result
As reported in the abstract
Dactylitis at baseline
Patients with dactylitis at baseline
389 of 996
39%
Further findings
Structural radiographic progression (van der Heijde-modified total Sharp score) · 2 years
- Patients without structural radiographic progression with secukinumab
- >80%
- Non-structural radiographic progressors comparable across patients with/without dactylitis at baseline with secukinumab
Joints, enthesitis, skin psoriasis, nail outcomes, physical function and health-related quality of life (HRQoL) in patients with dactylitis at baseline · 2 years
- Improvements sustained over 2 years
Original publication
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study. Clin Exp Rheumatol. Published 28 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →